United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

27 Jul 2016
Change (% chg)

-- (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CLSN.OQ


Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)


Beta: 2.23
Market Cap(Mil.): $30.00
Shares Outstanding(Mil.): 23.44
Dividend: --
Yield (%): --


  CLSN.OQ Industry Sector
P/E (TTM): -- 42.42 37.52
EPS (TTM): -0.94 -- --
ROI: -50.86 -9.34 14.48
ROE: -100.79 -9.70 15.65

BRIEF-Celsion Corp says updates on OVATION study

* Celsion Corp says announces positive data from OVATION study Source text for Eikon: Further company coverage:

Jul 25 2016

BRIEF-Celsion Corp announces $6 mln registered direct offering

* Celsion corporation announces $6 million registered direct offering

Jun 13 2016

BRIEF-Celsion expects to report translational data from first two cohorts of ovation study in Q3

* Celsion Corp Says Has Completed Enrollment Of Second Cohort Of Ovation Study And Expects To Report Clinical Data From That Cohort Mid Year

May 24 2016

BRIEF-Celsion Corp Q1 loss per share $0.24

* Celsion corporation reports first quarter 2016 financial results and provides business update

May 16 2016

BRIEF-Celsion announces positive data from first cohort of patients in ovation study

* Celsion corp says celsion expects to complete ovation study this year

May 02 2016


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.